Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 3Carcinoma, Squamous Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neoplasm Metastasis 1Mycosis Fungoides 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Carcinoma, Merkel Cell 1Breast Carcinoma In Situ 1

Interventions

talimogene laherparepvec 1rilotumumab 1lipoplatin 1ganitumab 1cediranib 1Zoledronic Acid 1Verteporfin 1Thoracentesis 1Therapeutics 1Talc 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Spectrum Analysis 1Sodium Chloride 1SPI-77, liposomal 1Radiotherapy, Conformal 1Photochemotherapy 1Nivolumab 1Naproxen 1Immunohistochemistry 1Fluorodeoxyglucose F18 1Fentanyl 1Etoposide 1Drug Therapy 1Doxycycline 1Dihematoporphyrin Ether 1Darbepoetin alfa 1Coal Tar 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pleural Effusion, Malignant × talimogene laherparepvec × Clear all
NCT03597009 2021-04-20

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Terminated
1 enrolled 12 charts
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡